Interferon Beta-1A
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Interferon Beta-1A
Interferon Beta-1A: Known uses and market status in Canada
Summary
All candidates that the TxGNN model produced for Interferon Beta-1A (score ≥ 0.99) and that can be traced to a source are already known uses. There is therefore currently no new predicted indication for this drug. The one known use is relapsing-remitting multiple sclerosis, supported by a licence in another country.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| relapsing-remitting multiple sclerosis | licence in another country (approved indication: multiple sclerosis) |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02318261 | REBIF | Valid | |
| 02237319 | REBIF | Valid | |
| 02318253 | REBIF | Valid | |
| 02269201 | AVONEX | Valid | |
| 02237320 | REBIF | Valid |
Safety Considerations
- Drug Interactions: 100 interactions were recorded. Among the 20 listed in the compiled data, one is rated Major: bupropion. The rest are rated Moderate, including acarbose, pioglitazone, rosiglitazone, clarithromycin, levofloxacin, minocycline, naltrexone, rosuvastatin, simvastatin, orlistat, and the anabolic steroids oxandrolone, oxymetholone and stanozolol.
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.